Actionable news
All posts from Actionable news
Actionable news in ICPT: Intercept Pharmaceuticals, Inc.,

FDA Panel Backs Intercept's Liver Disease Drug

Today Intercept Pharmaceuticals (ICPT) announced that an FDA advisory panel has backed its drug Ocaliva -- Obeticholic acid -- for the treatment of a rare liver disease known as primary billary cirrhosis -- PBC. This is a rare liver disease in which the body mistakes the liver ducts as foreign objects and attacks the linings.

The panel voted and concluded that obeticholic acid should be accelerated for approval to treat patients with PBC. What's even more impressive is that the panel backed the drug with a unanimous vote of 17-0.. With this positive vote outcome in...